SCHEMBL2409480

SCHEMBL2409480

O=C(O)NCCc1cn(S(=O)(=O)c2ccc(O)cc2)c(-c2cccnc2F)c1F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDE P14735 4/20 0.35
NAMPT P43490 2/20 0.34
CYP2C9 P11712 1/20 0.34
HTR6 P50406 5/20 0.33
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33
HDAC11 Q96DB2 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
HDAC9 Q9UKV0 1/20 0.33
HDAC5 Q9UQL6 1/20 0.33
ALDH1A1 P00352 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
TSHR P16473 1/20 0.32
HTT P42858 1/20 0.32
PTGDR2 Q9Y5Y4 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2194096 0.89 NAMPT (0.35) IDENAMPTCYP2C9HTR6ALDH1A1
SCHEMBL5002797 0.89 HTR6 (0.40) HTR6HDAC1HDAC6ALDH1A1
SCHEMBL2413187 0.88 ALDH1A1 (0.40) IDENAMPTCYP2C9HTR6ALDH1A1
SCHEMBL5008220 0.87 IDE (0.40) IDENAMPTHTR6HDAC3HDAC4
SCHEMBL5005956 0.86 IDE (0.38) IDENAMPTCYP2C9
SCHEMBL5008200 0.86 HIF1A (0.33) IDENAMPTCYP2C9
SCHEMBL2407109 0.86 IDE (0.34) IDENAMPTCYP2C9ALDH1A1SMN1; SMN2
SCHEMBL5002944 0.86 NPC1 (0.37) IDENAMPTCYP2C9HTR6GRM4
SCHEMBL2193985 0.86 DCTPP1 (0.35) IDENAMPTCYP2C9ALDH1A1PTGDR2
SCHEMBL5003164 0.85 MET (0.40) IDENAMPTCYP2C9HTR6HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2114917-B1 PYRROLE COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2016-08-10 EP disclosed
US-8933105-B2 Pyrrole compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-01-13 US disclosed
EP-2364979-A1 Pyrrole compounds Takeda Pharmaceutical Company Limited (JP) 2011-09-14 EP disclosed
US-20080262042-A1 1-[5-(2-Fluoropyridin-3-yl)-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine or a salt thereof; acid secretion inhibitor; potassium-competitive acid blocker TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262042-A1 1-[5-(2-Fluoropyridin-3-yl)-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine or a salt thereof; acid secretion inhibitor; potassium-competitive acid blocker REN, HRH2, ATP4A IDE 1224/4885NAMPT 2724/4885CYP2C9 1954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.